Please ensure Javascript is enabled for purposes of website accessibility

Aphria Notches Convincing Second-Quarter Beats

By Eric Volkman - Updated Jan 14, 2021 at 4:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The marijuana company had quite a pleasant surprise on the bottom line in particular.

In what are still all-too-rare occurrences in the marijuana industry, on Thursday Aphria (APHA) announced that it beat analyst estimates in its latest quarter, and even squeezed out a small profit.

The Canadian company reported that its net revenue for the second quarter of fiscal 2021 was 160.5 million Canadian dollars ($126.2 million). That was a robust 33% higher on a year-over-year basis, and 10% above the first-quarter tally.

On an adjusted basis, Aphria flipped to a profit of CA$3.2 million, or CA$0.01 per share. That compared very favorably to the year-ago loss of nearly CA$48.8 million; a comparable figure for the first quarter was not readily available.

Marijuana flower on fire.

Image source: Getty Images.

Regardless, the pair of second-quarter headline numbers were better than expected. On average, analysts following Aphria had forecast a top line of just under $119.4 million in U.S. dollars for net revenue, and a per-share net loss of $0.02.

Aphria attributed its quarter-over-quarter growth to higher distribution revenue from CC Pharma, its medical marijuana distributor in Germany. But all in all, its average retail selling price in the medical category dropped to CA$6.96 per gram from the first quarter's CA$7.38.

This was due, the company wrote, to "specific pricing programs offered to assist patients in need who have been negatively impacted by the COVID-19 pandemic, along with other promotional programs."

Recreational weed saw a slight uptick, by contrast, rising to CA$4.29 per gram against the previous quarter's CA$4.15. Aphria attributed this to shifts in its sales mix.

Bottom-line profit is the rare high that cannabis investors continue to chase, so it was no wonder Aphria shares rocketed 21% on Thursday, against a modest decline in the S&P 500 index.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aphria Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.